Does the risk factor profile have predictive value for the site of atherosclerosis?

Por Sinzinger, H
Publicado em 2005

Professional athletes suffering from familial hypercholesterolaemia rarely tolerate statin treatment because of muscular problems

Por Sinzinger, H, O'Grady, J
Publicado em 2004

MED32/442: Internet Lectures: A five years experience at the University of Vienna

Por Kritz, H, Najemnik, C, Sinzinger, H
Publicado em 1999

Prostacyclin activity in rat kidney stimulated by angiotensin II.

Por Silberbauer, K., Sinzinger, H., Winter, M.
Publicado em 1979

Decrease of prostaglandin I2 binding sites in thyroid cancer.

Por Virgolini, I., Hermann, M., Sinzinger, H.
Publicado em 1988

The influence of irradiation on the biological half-life of prostacyclin in plasma of patients with gastrointestinal cancer.

Por Polterauer, P., Sinzinger, H., Peskar, B. A.
Publicado em 1987

Effect of prostaglandin E1 on deposition of autologous labelled platelets onto human atherosclerotic lesions in vivo.

Por Sinzinger, H., O'Grady, J., Fitscha, P.
Publicado em 1987

Long-term improvement in left ventricular ejection fraction during continuous PGE1-therapy in a patient with congestive cardiomyopathy.

Por Sinzinger, H., O'Grady, J., Rogatti, W.
Publicado em 1988

Prostaglandin I2 and the nitric oxide donor molsidomine have synergistic effects on thromboresistance in man.

Por Sinzinger, H, Rauscha, F, O'Grady, J, Fitscha, P
Publicado em 1992

Human hepatocellular cancers show decreased prostaglandin E1 binding capacity.

Por Virgolini, I., Sinzinger, H., Müller, C., Hermann, M.
Publicado em 1989

Stabilization of endothelial lining and decrease in circulating endothelial cells--one mechanism underlying the clinical action of PGE1?

Por Sinzinger, H, Virgolini, I, Fitscha, P, Rauscha, F, Kaliman, J
Publicado em 1988

99mTc-neoglycoalbumin (NGA)-binding to human hepatic binding protein (HBP) in vitro.

Por Virgolini, I, Angelberger, P, Müller, C, O'Grady, J, Sinzinger, H
Publicado em 1990

Development of optimal infusion regimens for epoprostenol using radio labelled platelet uptake over atherosclerotic lesions in man.

Por Sinzinger, H, Fitscha, P, Kaliman, J, Silberbauer, K, O'Grady, J
Publicado em 1987

Prostaglandin E1 decreases the low-density-lipoprotein entry into rabbit arterial wall.

Por Sinzinger, H., Virgolini, I., Lupattelli, G., Molinari, E., Gerakakis, A., Angelberger, P.
Publicado em 1991

Decreased hepatic function in patients with hepatoma or liver metastasis monitored by a hepatocyte specific galactosylated radioligand.

Por Virgolini, I., Müller, C., Klepetko, W., Angelberger, P., Bergmann, H., O'Grady, J., Sinzinger, H.
Publicado em 1990

Scintigraphic evaluation of functional hepatic mass in patients with advanced breast cancer.

Por Virgolini, I., Kornek, G., Höbart, J., Li, S. R., Raolerer, M., Bergmann, H., Scheithauer, W., Pantev, T., Angelberger, P., Sinzinger, H.
Publicado em 1993